Zealand Pharma A/S (NASDAQ: ZEAL) announced that its partner Boehringer Ingelheim reported positive results from a Phase III trial of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE